Low-Grade Glioma Treatment Market Size in the 7MM was ~USD 990 Million in 2023 and It is projected to Grow at a significant CAGR by 2034 | DelveInsight

DelveInsight's "Low-Grade Glioma Treatment Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Low-Grade Glioma, historical and forecasted epidemiology as well as Low-Grade Glioma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Low-Grade Glioma Treatment Market Report @ https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Low-Grade Glioma Market Report
• In May 2026, Day One Biopharmaceuticals and Servier have completed patient enrollment for their pivotal Phase 3 FIREFLY-2 / LOGGIC clinical trial evaluating tovorafenib, a selective type II RAF inhibitor, as a frontline, initial monotherapy for pediatric low-grade glioma (pLGG). As pLGG is the most common central nervous system tumor diagnosed in children, achieving full enrollment is a major milestone toward establishing a targeted, oral treatment option that could bypass the severe, long-term toxicities associated with traditional chemotherapy and potentially reshape the pediatric standard of care.
• The total Low Grade Glioma Incident cases in the 7MM was more than 9000 in 2023.
• Among the 7MM, the US accounted for the highest number of Low Grade Glioma incidence cases in 2023, with more than 3700 cases; these cases are expected to increase during the forecast period.
• In the United States, the number of Grade 2 glioma cases was higher than the Grade I glioma in 2023
• Among the type-specific cases, the cases of Diffuse Astrocytoma accounted for the highest number in the US, followed by Pilocytic Astrocytoma in 2023.
• Among EU4 and the UK, Germany accounted for the highest number of cases of Low-grade Glioma, followed by France, while Spain occupied the bottom of the ladder in 2023.
• The leading Low-Grade Glioma Companies include Day One Biopharmaceuticals, AnHeart Therapeutics, BeiGene, Merck & Co., Inc., Bristol Myers Squibb, Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca plc, Sanofi S.A., Johnson & Johnson, Eli Lilly and Company, AbbVie Inc., Takeda Pharmaceutical Company Limited, Celgene Corporation, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., Biogen Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Bayer AG, Astellas Pharma Inc. and others.
• Promising Low-Grade Glioma Therapies include TAFINLAR (dabrafenib), OJEMDA (tovorafenib), Vorasidenib, Safusidenib/AB-218, Mirdametinib and others.

Get a Free sample for the Low-Grade Glioma Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Low-Grade Glioma Overview
Low-grade gliomas are a diverse group of primary brain tumors that often arise in young, otherwise healthy patients and generally have an indolent course with longer-term survival in comparison with high-grade glioma. Moreover, in this type of brain tumor with a relatively good prognosis and prolonged survival, the potential benefits of treatment must be carefully weighed against potential treatment-related risks. Low-grade astrocytic tumors include diffuse astrocytoma, pilomyxoid astrocytoma, pleomorphic xanthoastrocytoma (WHO grade II), as well as subependymal giant cell astrocytoma (SEGA), and pilocytic astrocytoma (WHO grade I tumors). IDH1 and IDH2 are the most commonly mutated genes in low-grade glioma, with mutations estimated to occur in > 70% of cases. BRAF V600E point mutations are occasionally observed in pilocytic astrocytoma; the mutations are also observed in non pilocytic pediatric low-grade glioma, including ganglioglioma, desmoplastic infantile ganglioglioma, and approximately two-thirds of pleomorphic xanthoastrocytomas.

Low-Grade Glioma Epidemiology Segmentation in the 7MM
• Total Low-Grade Glioma Incident Cases
• Low-Grade Glioma Stage-Specific Incident Cases
• Total Low-Grade Glioma Incidence Cases
• Total Low-Grade Glioma Incident Cases
• Total Low-Grade Glioma Diagnosed Incident Cases
• Low-Grade Glioma Age-Specific Cases

Download the report to understand which factors are driving Low-Grade Glioma epidemiology trends @ https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Low Grade Glioma Marketed Drugs

• TAFINLAR (dabrafenib) + MEKINIST (trametinib): Novartis
Trametinib + dabrafenib is an oral small-molecule inhibitor that inhibits the MAPK pathway and cell growth of various BRAFV600E-positive tumors. In June 2022, Novartis announced that the US FDA granted accelerated approval to TAFINLAR (dabrafenib) + MEKINIST (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.

• OJEMDA (tovorafenib): Day One Biopharmaceuticals
Tovorafenib is an investigational, oral, selective, central nervous system-penetrant, type II RAF inhibitor with activity against monomeric and dimeric forms of RAS signaling. Unlike type I BRAF inhibitors, tovorafenib does not lead to paradoxical activation of the MAPK pathway. On 23 April 2024, the US FDA granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF V600 mutation. This approval was based on results from the Phase II FIREFLY-1 trial.

Low Grade Glioma Emerging Drugs Profile

• Vorasidenib: Servier
Servier is developing Vorasidenib an investigational, oral, selective, brain-penetrant dual inhibitor of mutant IDH1 and IDH2 enzymes. The drug is currently being evaluated in the registration-enabling Phase III INDIGO study as a potential treatment for patients with residual or recurrent Grade 2 low-grade glioma with an IDH1 or IDH2 mutation (NCT04164901). The company has also announced promising Phase I data for Vorasidenib in IDH mutant low-grade glioma. The study data demonstrated a median progression-free survival of 36.8 months (3.1 years) for patients with non-enhancing low-grade glioma and demonstrated a favorable safety profile. This drug is also being evaluated in a Phase I trial for grade II/III glioma with an IDH1 R132H mutation (NCT03343197).

• Safusidenib/AB-218: Nuvation Bio
Nuvation Bio is currently studying AB-218 in patients with IDH1 mutant Glioma. AB-218 is a novel, potent, highly selective mutant IDH-1 inhibitor, which has high permeability of the blood-brain barrier and has demonstrated encouraging safety and efficacy signals in a Phase I trial of glioma patients. The company has initiated a Phase II trial in participants with recurrent or progressive histologically confirmed IDH1 mutant WHO Grade 2/3 glioma for which the recruitment has not yet started. The drug was originally developed by Daiichi Sankyo but in 2020 AnHeart Therapeutics acquired this drug. The Phase I clinical trial of AB-218 in glioma patients has demonstrated promising efficacy and safety profiles in 12 non-enhancing and 35 enhancing glioma patients.

• Mirdametinib: SpringWorks Therapeutics
Mirdametinib is an oral, allosteric, brain-penetrant small molecule designed to inhibit MEK1 and MEK2, which are proteins that occupy pivotal positions in the MAPK pathway. SpringWorks Therapeutics reported the initiation of a Phase I/II clinical trial to evaluate Mirdametinib, an investigational MEK inhibitor, for the treatment of children, adolescents, and young adults with LGG.

Low-Grade Glioma Companies
Day One Biopharmaceuticals, AnHeart Therapeutics, BeiGene, Merck & Co., Inc., Bristol Myers Squibb, Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca plc, Sanofi S.A., Johnson & Johnson, Eli Lilly and Company, AbbVie Inc., Takeda Pharmaceutical Company Limited, Celgene Corporation, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., Biogen Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Bayer AG, Astellas Pharma Inc. and others.

Discover more about therapies set to grab Major Low-Grade Glioma market share @ https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Low-Grade Glioma Market Outlook
The standard of care consists of maximum safe resection, the potential use of chemoradiation for high-risk patients, and lifelong radiographic surveillance, with the goal of treatment to delay malignant transformation and maximize the quality of life. The optimal treatment of low-grade glioma (particularly the timing) is controversial, and treatment decisions must balance the benefits of therapy against the potential for treatment-related complications. Surgery, radiation therapy, and chemotherapy may be used to treat a low-grade glioma, either separately or in combination. Tumor shrinkage has been seen in selected patients using various drugs or combinations, such as temozolomide or the "PCV" combination (procarbazine, lomustine, and vincristine).

Low-Grade Glioma Treatment Landscape
Tovorafenib was approved as a treatment for patients 6 months of age and older with certain relapsed or refractory pediatric low-grade glioma (pLGG). The nod sanctions the type 2 RAF inhibitor to be used in tumors with a BRAF fusion or rearrangement, or BRAF V600 mutation. Low-grade glioma is the most common pediatric brain cancer. BRAF V600 mutations are present in 15-20% of pediatric Low-grade glioma and are associated with poor survival outcomes and less favorable response to chemotherapy. BRAF mutations have been identified as drivers of cancer growth, the FDA has also previously approved TAFINLAR + MEKINIST by Novartis to treat pediatric patients with LGG with a BRAF V600E mutation who require systemic therapy; however, this indication is for patients who are 1 year of age and older.

To know more about Low-Grade Glioma Companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Low-Grade Glioma Market Report
• Coverage- 7MM
• Study Period: 2020-2034
• Forecast Period- 2024-2034
• Low-Grade Glioma Companies- Day One Biopharmaceuticals, AnHeart Therapeutics, BeiGene, Merck & Co., Inc., Bristol Myers Squibb, Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca plc, Sanofi S.A., Johnson & Johnson, Eli Lilly and Company, AbbVie Inc., Takeda Pharmaceutical Company Limited, Celgene Corporation, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., Biogen Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Bayer AG, Astellas Pharma Inc. and others.
• Low-Grade Glioma Therapies- TAFINLAR (dabrafenib), OJEMDA (tovorafenib), Vorasidenib, Safusidenib/AB-218, Mirdametinib and others.
• Low-Grade Glioma Therapeutic Assessment- Low-Grade Glioma current marketed and Low-Grade Glioma emerging therapies
• Low-Grade Glioma Market Dynamics: Low-Grade Glioma market drivers and Low-Grade Glioma market barriers
• Low-Grade Glioma Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Low-Grade Glioma Unmet Needs, KOL's views, Analyst's views, Low-Grade Glioma Market Access and Reimbursement

Table of Contents
1. Low-Grade Glioma Market Report Introduction
2. Executive Summary for Low-Grade Glioma
3. SWOT analysis of Low-Grade Glioma
4. Low-Grade Glioma Patient Share (%) Overview at a Glance
5. Low-Grade Glioma Market Overview at a Glance
6. Low-Grade Glioma Disease Background and Overview
7. Low-Grade Glioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Low-Grade Glioma
9. Low-Grade Glioma Current Treatment and Medical Practices
10. Low-Grade Glioma Unmet Needs
11. Low-Grade Glioma Emerging Therapies
12. Low-Grade Glioma Market Outlook
13. Country-Wise Low-Grade Glioma Market Analysis
14. Low-Grade Glioma Market Access and Reimbursement of Therapies
15. Low-Grade Glioma Market Drivers
16. Low-Grade Glioma Market Barriers
17. Low-Grade Glioma Appendix
18. Low-Grade Glioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.